nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—Decreased appetite—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Rifaximin—Confusional state—Lisinopril—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Rifaximin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Rifaximin—Headache—Mometasone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Rifaximin—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Insomnia—Mycophenolic acid—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Fatigue—Leflunomide—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Pruritus—Captopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Rifaximin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Pain—Leflunomide—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Constipation—Leflunomide—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Infection—Lisinopril—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Rifaximin—Shock—Lisinopril—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Rifaximin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Rifaximin—Neutropenia—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Rifaximin—Abdominal pain—Azathioprine—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Rifaximin—Body temperature increased—Azathioprine—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Rifaximin—Skin disorder—Lisinopril—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Rifaximin—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Diarrhoea—Captopril—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Feeling abnormal—Leflunomide—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Fatigue—Mycophenolic acid—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Nausea—Mometasone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Anorexia—Lisinopril—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Weight increased—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Rifaximin—Pain—Mycophenolic acid—systemic scleroderma	0.001	0.001	CcSEcCtD
Rifaximin—Constipation—Mycophenolic acid—systemic scleroderma	0.001	0.001	CcSEcCtD
Rifaximin—Weight decreased—Prednisone—systemic scleroderma	0.001	0.001	CcSEcCtD
Rifaximin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000999	0.000999	CcSEcCtD
Rifaximin—Hyperglycaemia—Prednisone—systemic scleroderma	0.000997	0.000997	CcSEcCtD
Rifaximin—Cough—Mycophenolate mofetil—systemic scleroderma	0.000992	0.000992	CcSEcCtD
Rifaximin—Hypotension—Lisinopril—systemic scleroderma	0.000989	0.000989	CcSEcCtD
Rifaximin—Dizziness—Captopril—systemic scleroderma	0.000988	0.000988	CcSEcCtD
Rifaximin—Depression—Prednisone—systemic scleroderma	0.000983	0.000983	CcSEcCtD
Rifaximin—Urticaria—Leflunomide—systemic scleroderma	0.000979	0.000979	CcSEcCtD
Rifaximin—Body temperature increased—Leflunomide—systemic scleroderma	0.000974	0.000974	CcSEcCtD
Rifaximin—Abdominal pain—Leflunomide—systemic scleroderma	0.000974	0.000974	CcSEcCtD
Rifaximin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000968	0.000968	CcSEcCtD
Rifaximin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000967	0.000967	CcSEcCtD
Rifaximin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000967	0.000967	CcSEcCtD
Rifaximin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000967	0.000967	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000964	0.000964	CcSEcCtD
Rifaximin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000961	0.000961	CcSEcCtD
Rifaximin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000961	0.000961	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000961	0.000961	CcSEcCtD
Rifaximin—Insomnia—Lisinopril—systemic scleroderma	0.000957	0.000957	CcSEcCtD
Rifaximin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000956	0.000956	CcSEcCtD
Rifaximin—Vomiting—Captopril—systemic scleroderma	0.00095	0.00095	CcSEcCtD
Rifaximin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000946	0.000946	CcSEcCtD
Rifaximin—Dyspnoea—Lisinopril—systemic scleroderma	0.000944	0.000944	CcSEcCtD
Rifaximin—Rash—Captopril—systemic scleroderma	0.000942	0.000942	CcSEcCtD
Rifaximin—Dermatitis—Captopril—systemic scleroderma	0.000942	0.000942	CcSEcCtD
Rifaximin—Headache—Captopril—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Rifaximin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000935	0.000935	CcSEcCtD
Rifaximin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Rifaximin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Rifaximin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000927	0.000927	CcSEcCtD
Rifaximin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000921	0.000921	CcSEcCtD
Rifaximin—Decreased appetite—Lisinopril—systemic scleroderma	0.00092	0.00092	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000914	0.000914	CcSEcCtD
Rifaximin—Fatigue—Lisinopril—systemic scleroderma	0.000913	0.000913	CcSEcCtD
Rifaximin—Shock—Mycophenolate mofetil—systemic scleroderma	0.000912	0.000912	CcSEcCtD
Rifaximin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000909	0.000909	CcSEcCtD
Rifaximin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000908	0.000908	CcSEcCtD
Rifaximin—Pain—Lisinopril—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Rifaximin—Constipation—Lisinopril—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Rifaximin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000901	0.000901	CcSEcCtD
Rifaximin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000897	0.000897	CcSEcCtD
Rifaximin—Diarrhoea—Azathioprine—systemic scleroderma	0.000892	0.000892	CcSEcCtD
Rifaximin—Haemoglobin—Prednisone—systemic scleroderma	0.000889	0.000889	CcSEcCtD
Rifaximin—Nausea—Captopril—systemic scleroderma	0.000888	0.000888	CcSEcCtD
Rifaximin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000886	0.000886	CcSEcCtD
Rifaximin—Haemorrhage—Prednisone—systemic scleroderma	0.000885	0.000885	CcSEcCtD
Rifaximin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000884	0.000884	CcSEcCtD
Rifaximin—Asthenia—Leflunomide—systemic scleroderma	0.000884	0.000884	CcSEcCtD
Rifaximin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000872	0.000872	CcSEcCtD
Rifaximin—Pruritus—Leflunomide—systemic scleroderma	0.000872	0.000872	CcSEcCtD
Rifaximin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000867	0.000867	CcSEcCtD
Rifaximin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000866	0.000866	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—systemic scleroderma	0.000864	0.000864	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—systemic scleroderma	0.000864	0.000864	CcSEcCtD
Rifaximin—Dizziness—Azathioprine—systemic scleroderma	0.000863	0.000863	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000859	0.000859	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000845	0.000845	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Rifaximin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Rifaximin—Diarrhoea—Leflunomide—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Rifaximin—Urticaria—Lisinopril—systemic scleroderma	0.000841	0.000841	CcSEcCtD
Rifaximin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000839	0.000839	CcSEcCtD
Rifaximin—Abdominal pain—Lisinopril—systemic scleroderma	0.000837	0.000837	CcSEcCtD
Rifaximin—Body temperature increased—Lisinopril—systemic scleroderma	0.000837	0.000837	CcSEcCtD
Rifaximin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000831	0.000831	CcSEcCtD
Rifaximin—Vomiting—Azathioprine—systemic scleroderma	0.000829	0.000829	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—systemic scleroderma	0.000829	0.000829	CcSEcCtD
Rifaximin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000827	0.000827	CcSEcCtD
Rifaximin—Infestation—Methotrexate—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Rifaximin—Rash—Azathioprine—systemic scleroderma	0.000822	0.000822	CcSEcCtD
Rifaximin—Dermatitis—Azathioprine—systemic scleroderma	0.000822	0.000822	CcSEcCtD
Rifaximin—Depression—Methotrexate—systemic scleroderma	0.000821	0.000821	CcSEcCtD
Rifaximin—Flushing—Prednisone—systemic scleroderma	0.000821	0.000821	CcSEcCtD
Rifaximin—Headache—Azathioprine—systemic scleroderma	0.000817	0.000817	CcSEcCtD
Rifaximin—Dizziness—Leflunomide—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Rifaximin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000806	0.000806	CcSEcCtD
Rifaximin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000804	0.000804	CcSEcCtD
Rifaximin—Angiopathy—Prednisone—systemic scleroderma	0.000803	0.000803	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000801	0.000801	CcSEcCtD
Rifaximin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000793	0.000793	CcSEcCtD
Rifaximin—Pain—Mycophenolate mofetil—systemic scleroderma	0.000793	0.000793	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—systemic scleroderma	0.000785	0.000785	CcSEcCtD
Rifaximin—Vomiting—Leflunomide—systemic scleroderma	0.000783	0.000783	CcSEcCtD
Rifaximin—Hypersensitivity—Lisinopril—systemic scleroderma	0.00078	0.00078	CcSEcCtD
Rifaximin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Rifaximin—Rash—Leflunomide—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Rifaximin—Dermatitis—Leflunomide—systemic scleroderma	0.000776	0.000776	CcSEcCtD
Rifaximin—Mental disorder—Prednisone—systemic scleroderma	0.000775	0.000775	CcSEcCtD
Rifaximin—Nausea—Azathioprine—systemic scleroderma	0.000775	0.000775	CcSEcCtD
Rifaximin—Headache—Leflunomide—systemic scleroderma	0.000772	0.000772	CcSEcCtD
Rifaximin—Malnutrition—Prednisone—systemic scleroderma	0.00077	0.00077	CcSEcCtD
Rifaximin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000764	0.000764	CcSEcCtD
Rifaximin—Asthenia—Lisinopril—systemic scleroderma	0.000759	0.000759	CcSEcCtD
Rifaximin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000758	0.000758	CcSEcCtD
Rifaximin—Pruritus—Lisinopril—systemic scleroderma	0.000749	0.000749	CcSEcCtD
Rifaximin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000747	0.000747	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—systemic scleroderma	0.000743	0.000743	CcSEcCtD
Rifaximin—Rash—Mycophenolic acid—systemic scleroderma	0.000741	0.000741	CcSEcCtD
Rifaximin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—systemic scleroderma	0.000739	0.000739	CcSEcCtD
Rifaximin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000737	0.000737	CcSEcCtD
Rifaximin—Headache—Mycophenolic acid—systemic scleroderma	0.000736	0.000736	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—systemic scleroderma	0.000734	0.000734	CcSEcCtD
Rifaximin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Rifaximin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Rifaximin—Nausea—Leflunomide—systemic scleroderma	0.000732	0.000732	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00073	0.00073	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Rifaximin—Diarrhoea—Lisinopril—systemic scleroderma	0.000724	0.000724	CcSEcCtD
Rifaximin—Ill-defined disorder—Prednisone—systemic scleroderma	0.000715	0.000715	CcSEcCtD
Rifaximin—Anaemia—Prednisone—systemic scleroderma	0.000712	0.000712	CcSEcCtD
Rifaximin—Angioedema—Prednisone—systemic scleroderma	0.000704	0.000704	CcSEcCtD
Rifaximin—Dizziness—Lisinopril—systemic scleroderma	0.0007	0.0007	CcSEcCtD
Rifaximin—Nausea—Mycophenolic acid—systemic scleroderma	0.000698	0.000698	CcSEcCtD
Rifaximin—Malaise—Prednisone—systemic scleroderma	0.000695	0.000695	CcSEcCtD
Rifaximin—Vertigo—Prednisone—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Rifaximin—Syncope—Prednisone—systemic scleroderma	0.000691	0.000691	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—systemic scleroderma	0.000689	0.000689	CcSEcCtD
Rifaximin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000683	0.000683	CcSEcCtD
Rifaximin—Loss of consciousness—Prednisone—systemic scleroderma	0.000677	0.000677	CcSEcCtD
Rifaximin—Vomiting—Lisinopril—systemic scleroderma	0.000673	0.000673	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Rifaximin—Rash—Lisinopril—systemic scleroderma	0.000667	0.000667	CcSEcCtD
Rifaximin—Dermatitis—Lisinopril—systemic scleroderma	0.000667	0.000667	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000666	0.000666	CcSEcCtD
Rifaximin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000665	0.000665	CcSEcCtD
Rifaximin—Headache—Lisinopril—systemic scleroderma	0.000663	0.000663	CcSEcCtD
Rifaximin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Rifaximin—Myalgia—Prednisone—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Rifaximin—Arthralgia—Prednisone—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Rifaximin—Discomfort—Prednisone—systemic scleroderma	0.000648	0.000648	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—systemic scleroderma	0.000648	0.000648	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—systemic scleroderma	0.000644	0.000644	CcSEcCtD
Rifaximin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000635	0.000635	CcSEcCtD
Rifaximin—Nausea—Lisinopril—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Rifaximin—Infection—Prednisone—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Rifaximin—Back pain—Methotrexate—systemic scleroderma	0.000623	0.000623	CcSEcCtD
Rifaximin—Shock—Prednisone—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Rifaximin—Nervous system disorder—Prednisone—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Rifaximin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000613	0.000613	CcSEcCtD
Rifaximin—Skin disorder—Prednisone—systemic scleroderma	0.000611	0.000611	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisone—systemic scleroderma	0.000608	0.000608	CcSEcCtD
Rifaximin—Anorexia—Prednisone—systemic scleroderma	0.000599	0.000599	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000597	0.000597	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Rifaximin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Rifaximin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Rifaximin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000584	0.000584	CcSEcCtD
Rifaximin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Rifaximin—Malaise—Methotrexate—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000573	0.000573	CcSEcCtD
Rifaximin—Insomnia—Prednisone—systemic scleroderma	0.000569	0.000569	CcSEcCtD
Rifaximin—Cough—Methotrexate—systemic scleroderma	0.000562	0.000562	CcSEcCtD
Rifaximin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Rifaximin—Decreased appetite—Prednisone—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000544	0.000544	CcSEcCtD
Rifaximin—Fatigue—Prednisone—systemic scleroderma	0.000542	0.000542	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Rifaximin—Constipation—Prednisone—systemic scleroderma	0.000538	0.000538	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—systemic scleroderma	0.00053	0.00053	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000525	0.000525	CcSEcCtD
Rifaximin—Infection—Methotrexate—systemic scleroderma	0.000522	0.000522	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisone—systemic scleroderma	0.000518	0.000518	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Rifaximin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—systemic scleroderma	0.00051	0.00051	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000508	0.000508	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Rifaximin—Urticaria—Prednisone—systemic scleroderma	0.000499	0.000499	CcSEcCtD
Rifaximin—Abdominal pain—Prednisone—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Rifaximin—Body temperature increased—Prednisone—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—systemic scleroderma	0.000491	0.000491	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisone—systemic scleroderma	0.000463	0.000463	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—systemic scleroderma	0.000453	0.000453	CcSEcCtD
Rifaximin—Asthenia—Prednisone—systemic scleroderma	0.000451	0.000451	CcSEcCtD
Rifaximin—Pain—Methotrexate—systemic scleroderma	0.000449	0.000449	CcSEcCtD
Rifaximin—Pruritus—Prednisone—systemic scleroderma	0.000445	0.000445	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—systemic scleroderma	0.000433	0.000433	CcSEcCtD
Rifaximin—Diarrhoea—Prednisone—systemic scleroderma	0.00043	0.00043	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00043	0.00043	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—systemic scleroderma	0.000417	0.000417	CcSEcCtD
Rifaximin—Dizziness—Prednisone—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Rifaximin—Vomiting—Prednisone—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Rifaximin—Rash—Prednisone—systemic scleroderma	0.000396	0.000396	CcSEcCtD
Rifaximin—Dermatitis—Prednisone—systemic scleroderma	0.000396	0.000396	CcSEcCtD
Rifaximin—Headache—Prednisone—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000387	0.000387	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—systemic scleroderma	0.000377	0.000377	CcSEcCtD
Rifaximin—Nausea—Prednisone—systemic scleroderma	0.000373	0.000373	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—systemic scleroderma	0.000359	0.000359	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—systemic scleroderma	0.000347	0.000347	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—systemic scleroderma	0.000334	0.000334	CcSEcCtD
Rifaximin—Rash—Methotrexate—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Rifaximin—Headache—Methotrexate—systemic scleroderma	0.000329	0.000329	CcSEcCtD
Rifaximin—Nausea—Methotrexate—systemic scleroderma	0.000312	0.000312	CcSEcCtD
